Tags

Type your tag names separated by a space and hit enter

A comparison of teriparatide and calcitonin therapy in postmenopausal Asian women with osteoporosis: a 6-month study.
Curr Med Res Opin. 2006 May; 22(5):929-37.CM

Abstract

OBJECTIVE

The number of hip fractures is expected to double in the next 20 years, with current estimates that Asia will account for 37% of these cases. As bone mineral density (BMD) may be used as a measure of fracture risk, we sought to compare the effects of teriparatide with salmon calcitonin treatment on changes in BMD, biochemical bone markers, and safety in postmenopausal Asian women with osteoporosis.

METHODOLOGY

A total of 104 patients (n = 47 teriparatide [20 g/day subcutaneously] and n = 57 calcitonin [100 IU/day subcutaneously]) were enrolled in Hong Kong, Singapore, Philippines, Malaysia, and Thailand. Calcium (> or = 500 mg/day) and vitamin D (200-400 IU/day) supplements were taken throughout the 6-month controlled, randomized study.

RESULTS

Teriparatide was associated with a 5.03 +/- 4.77% increase in lumbar spine BMD (p < 0.0001, mean +/- SD change from baseline), whereas changes in lumbar spine BMD for patients on calcitonin were not statistically significant (mean change of 0.36 +/- 4.12%, p = 0.16). Comparison of the two groups indicated that teriparatide treatment improved lumbar spine BMD statistically significantly more than calcitonin (p < 0.0001). No statistically significant changes were observed for total hip or femoral neck BMD. Serum bone-specific alkaline phosphatase (BSAP) increased by 55.9% (median change from baseline, p < 0.0001) in the teriparatide group, and remained stable with calcitonin (5.0% change, p = 0.24); osteocalcin increased by 156.15% (median change from baseline, p < 0.0001) with teriparatide, and decreased with calcitonin (-15.25%, p = 0.03). Similar rates of adverse events were observed, with nausea and dizziness the most commonly reported for both groups (teriparatide versus calcitonin, 13.0% versus 23.2% p = 0.21, 10.9% versus 21.4% p = 0.19, respectively). There were no clinically relevant changes observed in laboratory parameters.

CONCLUSIONS

Both treatments were similarly tolerated, however teriparatide was associated with greater increases in lumbar spine BMD and bone formation markers, demonstrating the unique mechanism of action and safety of this treatment for osteoporosis in these Asian women.

Authors+Show Affiliations

Dept of Medicine, University of Hong Kong, Queen Mary Hospital, China.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

16709314

Citation

Kung, A W C., et al. "A Comparison of Teriparatide and Calcitonin Therapy in Postmenopausal Asian Women With Osteoporosis: a 6-month Study." Current Medical Research and Opinion, vol. 22, no. 5, 2006, pp. 929-37.
Kung AW, Pasion EG, Sofiyan M, et al. A comparison of teriparatide and calcitonin therapy in postmenopausal Asian women with osteoporosis: a 6-month study. Curr Med Res Opin. 2006;22(5):929-37.
Kung, A. W., Pasion, E. G., Sofiyan, M., Lau, E. M., Tay, B. K., Lam, K. S., Wilawan, K., Ongphiphadhanakul, B., & Thiebaud, D. (2006). A comparison of teriparatide and calcitonin therapy in postmenopausal Asian women with osteoporosis: a 6-month study. Current Medical Research and Opinion, 22(5), 929-37.
Kung AW, et al. A Comparison of Teriparatide and Calcitonin Therapy in Postmenopausal Asian Women With Osteoporosis: a 6-month Study. Curr Med Res Opin. 2006;22(5):929-37. PubMed PMID: 16709314.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - A comparison of teriparatide and calcitonin therapy in postmenopausal Asian women with osteoporosis: a 6-month study. AU - Kung,A W C, AU - Pasion,E G, AU - Sofiyan,M, AU - Lau,E M C, AU - Tay,B K, AU - Lam,K S, AU - Wilawan,K, AU - Ongphiphadhanakul,B, AU - Thiebaud,D, PY - 2006/5/20/pubmed PY - 2006/9/23/medline PY - 2006/5/20/entrez SP - 929 EP - 37 JF - Current medical research and opinion JO - Curr Med Res Opin VL - 22 IS - 5 N2 - OBJECTIVE: The number of hip fractures is expected to double in the next 20 years, with current estimates that Asia will account for 37% of these cases. As bone mineral density (BMD) may be used as a measure of fracture risk, we sought to compare the effects of teriparatide with salmon calcitonin treatment on changes in BMD, biochemical bone markers, and safety in postmenopausal Asian women with osteoporosis. METHODOLOGY: A total of 104 patients (n = 47 teriparatide [20 g/day subcutaneously] and n = 57 calcitonin [100 IU/day subcutaneously]) were enrolled in Hong Kong, Singapore, Philippines, Malaysia, and Thailand. Calcium (> or = 500 mg/day) and vitamin D (200-400 IU/day) supplements were taken throughout the 6-month controlled, randomized study. RESULTS: Teriparatide was associated with a 5.03 +/- 4.77% increase in lumbar spine BMD (p < 0.0001, mean +/- SD change from baseline), whereas changes in lumbar spine BMD for patients on calcitonin were not statistically significant (mean change of 0.36 +/- 4.12%, p = 0.16). Comparison of the two groups indicated that teriparatide treatment improved lumbar spine BMD statistically significantly more than calcitonin (p < 0.0001). No statistically significant changes were observed for total hip or femoral neck BMD. Serum bone-specific alkaline phosphatase (BSAP) increased by 55.9% (median change from baseline, p < 0.0001) in the teriparatide group, and remained stable with calcitonin (5.0% change, p = 0.24); osteocalcin increased by 156.15% (median change from baseline, p < 0.0001) with teriparatide, and decreased with calcitonin (-15.25%, p = 0.03). Similar rates of adverse events were observed, with nausea and dizziness the most commonly reported for both groups (teriparatide versus calcitonin, 13.0% versus 23.2% p = 0.21, 10.9% versus 21.4% p = 0.19, respectively). There were no clinically relevant changes observed in laboratory parameters. CONCLUSIONS: Both treatments were similarly tolerated, however teriparatide was associated with greater increases in lumbar spine BMD and bone formation markers, demonstrating the unique mechanism of action and safety of this treatment for osteoporosis in these Asian women. SN - 0300-7995 UR - https://www.unboundmedicine.com/medline/citation/16709314/A_comparison_of_teriparatide_and_calcitonin_therapy_in_postmenopausal_Asian_women_with_osteoporosis:_a_6_month_study_ L2 - https://www.tandfonline.com/doi/full/10.1185/030079906X104768 DB - PRIME DP - Unbound Medicine ER -